Sharing Our Perspective - Archive

Sharing perspectives leads to greater understanding and fuels innovation. The ​Optum Insights Blog is where we share our perspective and challenge preconceptions to clear a new path forward.




  • Texas governor signs opioid control legislation

    by
    | Jun 21, 2019
    Tag Icon
    Pain Management, Pharmacy, Government Affairs, Opioids
    A new Texas law to curb opioid abuse includes prescribing restrictions for opioid treatment of acute pain. Effective September 1, 2019, when prescribing for treatment of acute pain, a provider may not prescribe opioids for more than a 10-day supply or refill an opioid.


  • Colorado doctors can now recommend medical marijuana as opioid alternative

    by
    | Jun 13, 2019
    Tag Icon
    Clinical Intervention, Clinical, Opioids, Government Affairs, Medical Marijuana
    The Colorado legislature has passed a law permitting physicians to recommend marijuana in lieu of opioids to treat certain disabling medical conditions. Senate Bill 13, gives providers greater leeway in discussing pain treatment options with their patients and is scheduled to take effect August 2, 2019.


  • Answers to Your Most Common Questions about Predictive Analytics in Workers’ Comp

    by
    • Optum for Workers' Compensation
    | May 16, 2019
    Tag Icon
    Analytics, Workers Comp, Clinical, Predictive Analytics
    Predictive analytics improve clinical outcomes and reduce costs for payers, but only if used properly. Risk & Insurance interviewed OWCA experts to learn how to apply predictive analytics in workers' compensation.


  • Our Industry Trends Report is now available

    by
    • Optum Workers' Comp
    | May 06, 2019
    Tag Icon
    Analytics, Ancillary, Drug Formulary, Medicare Set-Aside, Opioids, Optum Workers Comp Auto No Fault, Predictive Analytics, Settlement Solutions, Workers' Compensation
    A 2018 REVIEW OF THE PREVAILING INDUSTRY INFLUENCES IMPACTING CLAIM OUTCOMES


  • FDA approves the first generic naloxone nasal spray to treat opioid overdoses

    by
    • Optum for Workers' Compensation
    | Apr 29, 2019
    Tag Icon
    FDA approved, Clinical, Opioids, Narcan
    On April 19, the U.S. Food and Drug Administration (FDA) approved the first generic for Narcan® Nasal Spray, the life-saving medication used for the emergency treatment of opioid-related overdose.


  • Medication Recall: Two lots of fentanyl transdermal system (patch) recalled

    by
    • Optum for Workers' Compensation
    | Apr 25, 2019
    Tag Icon
    recall, Opioids, Fentanyl, Clinical, FDA
    The U.S. Food and Drug Administration (FDA) announced that Alvogen, Inc. voluntarily recalled two lots of fentanyl patches 12 mcg/hour at the consumer level.


  • FDA requires label changes for opioid analgesics to guide prescribers when gradual tapering is needed

    by
    • Optum Workers' Comp
    | Apr 15, 2019
    Tag Icon
    FDA, Pharmacy, Opioids, opioid analgesics, Clinical
    The U.S. Food and Drug Administration (FDA) issued a safety communication in early April that requires changes to prescribing information for opioid analgesics used in outpatient settings. The goal is to expand the information available to health care providers and patients when opioid analgesics have been prescribed and there is a need to safely decrease the dose or discontinue use of an opioid analgesic


  • New generic options available for Flector® Patch

    by
    | Mar 27, 2019
    Tag Icon
    Generics, Clinical
    Teva Pharmaceuticals has launched an authorized generic version of Flector Patch 1.3% (diclofenac epolamine topical patch), originally manufactured by Pfizer, in the United States (U.S.). Additionally, Greenstone, a Pfizer Company, is also launching an authorized generic version of Flector Patch.


  • PBM 101: A refresher on the role of pharmacy management in workers’ comp

    by
    • Katie Dwyer - Risk & Insurance
    | Mar 12, 2019
    Tag Icon
    Workers' Compensation, workers compensation, Workers Comp, PBM
    Increasingly, PBMs are relying on massive stores of data to identify broader patterns that inform individual prescription decisions. According to David Young, President and CEO of Optum Workers’ Compensation and Auto No-fault, this is a PBM’s true value proposition.


  • FDA advisory committees recommend approval of esketamine nasal spray for treatment-resistant depression

    by
    • Optum for Workers' Compensation
    | Feb 27, 2019
    Tag Icon
    FDA
    Treatment-resistant depression (TRD), is typically defined as failing trials of at least two antidepressant treatments for major depressive disorder. The FDA is expected to make its decision in early March. See potential impact for workers’ comp on our blog.


Stay informed by receiving latest updates

Do you have a question about a blog post?